MINNEAPOLIS--(BUSINESS WIRE)--Through five years following initial implantation in an FDA-approved study, the Talent Abdominal Stent Graft from Medtronic, Inc. (NYSE: MDT), demonstrated durable safety and effectiveness in patients with abdominal aortic aneurysms, despite having included patients with more challenging anatomies than comparable trials of similar medical devices.
